GLP-1 Drugs Tied to Mortality Reduction in Colon Cancer Patients With ObesityGLP-1 Drugs Tied to Mortality Reduction in Colon Cancer Patients With Obesity
(MedPage Today) — SAN FRANCISCO — Patients with colon cancer and comorbid obesity treated with GLP-1 receptor agonists had lower mortality and fewer serious non-cancer complications, a propensity-matched cohort study showed. The retrospective… (MedPage Today) — SAN FRANCISCO — Patients with colon cancer and comorbid obesity treated with GLP-1 receptor agonists had lower mortality Read More
ctDNA levels after neoadjuvant therapy may predict breast cancer recurrence better than pathologic complete responsectDNA levels after neoadjuvant therapy may predict breast cancer recurrence better than pathologic complete response
The presence of circulating tumor DNA (ctDNA) in patients with human epidermal growth factor receptor 2 (HER2)-positive breast cancer after they received neoadjuvant treatment and surgery predicted worse outcomes than in those patients without ctDNA, even in patients with a pathologic complete response (pCR), according to a study published in Cancer Research Communications.
FDA Says to Drop Suicide Warning From GLP-1 Drug LabelsFDA Says to Drop Suicide Warning From GLP-1 Drug Labels
(MedPage Today) — The FDA requested that manufacturers of GLP-1 receptor agonists remove information regarding risks of suicidal behavior and ideation from drug labels following a detailed review of existing data, the agency announced on Tuesday… (MedPage Today) — The FDA requested that manufacturers of GLP-1 receptor agonists remove information regarding risks of suicidal Read More
Blocking key enzyme to protect against fatty liver may raise cancer risk insteadBlocking key enzyme to protect against fatty liver may raise cancer risk instead
Scientists have discovered that blocking a key cellular enzyme thought to protect against fatty liver disease may instead increase the risk of chronic liver damage and cancer as we age.
Trump Talks About Taking GLP-1s; New MiniMed System OK’d; Testosterone in Diet RecsTrump Talks About Taking GLP-1s; New MiniMed System OK’d; Testosterone in Diet Recs
(MedPage Today) — President Trump said he’s never taken GLP-1 receptor agonists but said he “probably should.” (New York Times) People with diabetes and cancer lived longer and had lower hospitalization rates if they were taking GLP-1 drugs rather… (MedPage Today) — President Trump said he’s never taken GLP-1 receptor agonists but said he Read More
Serena Williams on Taking a GLP-1: ‘I Feel Like I’m Back’Serena Williams on Taking a GLP-1: ‘I Feel Like I’m Back’
The G.O.A.T. says we shouldn’t be shamed about what helps us feel better in our bodies. The G.O.A.T. says we shouldn’t be shamed about what helps us feel better in our bodies.
ACS Annual Statistics Report: Milestone 70 Percent 5-Year Survival Rate for all Cancers Combined; Largest Gains for Advanced and Fatal CancersACS Annual Statistics Report: Milestone 70 Percent 5-Year Survival Rate for all Cancers Combined; Largest Gains for Advanced and Fatal Cancers
This report marks the 75th year American Cancer Society researchers have analyzed and disseminated cancer data to help improve public health
Genetic Predisposition to Excess Body Weight and Breast Cancer SurvivalGenetic Predisposition to Excess Body Weight and Breast Cancer Survival
This cohort study investigates whether there is an association between a genetic predisposition to a greater body mass index and mortality risk among US women who survived nonmetastatic breast cancer.
New vulnerability identified in aggressive breast cancerNew vulnerability identified in aggressive breast cancer
Researchers at University of California San Diego have identified a previously unrecognized treatment target for triple‑negative breast cancer (TNBC), the most aggressive subtype of breast cancer. Their new study reveals that a protein called PUF60 plays an essential role in helping TNBC cells grow and survive by controlling how key genes are spliced.
Navigating Options After CDK4/6 Inhibition in Metastatic Breast CancerNavigating Options After CDK4/6 Inhibition in Metastatic Breast Cancer
(MedPage Today) — Clinicians treating patients with estrogen receptor (ER)-positive/HER2-negative metastatic breast cancer are navigating increasingly complex sequencing decisions in the post-CDK4/6 inhibitor setting, with antibody-drug conjugates…